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Abstract
Iran`s pharmaceutical products market has faced fluctuations over time. Suitable market 
selection is necessary for stability of pharmaceutical exports. This study aimed to determine 
the structure of the world pharmaceutical market and to identify the target of Iranian 
pharmaceutical export. T do so, concentration ratios and Herfindahl index were used to address 
the world pharmaceutical market from 2001 to 2012. Also, a composite index was used to 
identify the target markets of Iran’s pharmaceutical industry. The results showed that the export 
side of world pharmaceutical trade has shifted to open oligopoly, thereby decreasing the 
monopolistic power of exporters. The import side, however, follows monopolistic competition. 
It has been observed that the structure of Iran’s pharmaceutical export is shifting to open 
oligopoly; though, pharmaceutical importers from Iran have not been stable. Moreover, 27 
countries were identified as target markets. Due to significant differences between the current 
and potential export destinations of Iran’s pharmaceutical products, exporters should choose 
suitable strategies in order to diversify export markets. Such mechanisms as setting preferential 
tariffs on the basis of bilateral agreements, following effective advertisment, and paying 
attention to global consumers’preferences can be used to develop Iran’s pharmaceutical export 
to target countries.
Keywords: Pharmaceuticals; Concentration ratio; World market structure; Herfindahl 
index; Import and export; Target markets.
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Introduction
One of the most important strategies for 
economic development is to develop non-oil 
exports. In order to increase non-oil exports, it is 
imperative to identify products and production 
activities that can penetrate international 
markets. Unbalanced economic structures must 
be modified, advantageous export goods and 
potential export markets must be identified, and 
this process must be supported by governments 
(1).
Pharmaceutical industry is one of the 
industries that can significantly contribute to 
economic development and create added value 
(2). In many countries, this industry has evolved 
technologically and most pharmaceutical 
companies are very active in research and 
development (3). 
The important features of this industry are 
creating high added value products and 
significant employment (4). World 
pharmaceutical market is rapidly evolving. 
Iran’s pharmaceutical industry is regarded as an 
important and well-established industry with a 
special place in the Middle East. However, 
Iran’s share of the world pharmaceutical market 
is only 0.25 percent (5). 
The rate of return on Iran’s pharmaceutical 
industry is over 25 percent, which is higher than 
most domestic industries. It is almost on par 
with large pharmaceutical companies in terms of 
rate of return (6). Iran is among the top 20 
countries with the highest medicine consumption 
and is the third in Asia after Japan and China (7). 
The prevalence of self-medication is about 3 
times the world average, with pain killers and 
antibiotics being the most self-administered 
medicines (8). In addition to a population of 77 
million people with high drug use, Iran is located 
near a market of 47 million people in the 
southern end of the Persian Gulf where under 
development of health care has created an 
exceptional investment opportunity (9).
The development of pharmaceutical exports 
can lead to the growth of this sector. This not 
only has a direct impact on pharmaceutical 
products, but also improves labor and capital 
productivity (10). Identification of target markets 
focuses on marketing efforts and affects how 
resources are used (11).
Given the potential for production and 
development of pharmaceutical products in Iran 
and the high demand for Iranian pharmaceutical 
products among its neighboring countries, it is 
necessary to examine the structure of the world 
pharmaceutical market in order to increase 
production and exports and access to world 
markets, and to prioritize target markets in order 
to inform producers, exporters, and policy 
makers (12).
Iran’s trade policies emphasizes on non-oil 
export development, and the results of this study 
can provide useful insights for policy-makers in 
the pharmaceutical industry. Lack of investment 
in marketing and transport facilities and poor 
knowledge of pharmaceutical markets have 
reduced Iran’s pharmaceutical exports (13).
This paper tries to find how the structure of 
world pharmaceutical production and trade 
(imports and exports) has changed in the years 
of 2001-2012, the structure of Iran’s 
pharmaceutical export, the countries that can be 
potential target markets for Iran’s pharmaceutical 
exports, and the needs fulfilled to develop 
pharmaceutical export from Iran to target 
markets.
To our knowledge there has been no research 
on the world pharmaceutical market structure or 
target market prioritization similar to this study, 
but there have been studies on other industries in 
Iran and other countries briefly discussed in the 
following section. 
Hosseini and Hooman (2007) examined the 
world market structure of date palm and 
prioritized the target markets of Iran’s exports. 
The results indicated the oligopolistic structure 
of the world palm date production and the 
increasing share of Iran from the world market. 
Finally, 29 countries were prioritized as target 
markets for Iran’s palm date exports (14).
Abedin and Asgari (2005) prioritized the 
potential target markets for honey export from 
Iran. The results showed that the main honey 
importers from Iran were Turkey, United Arab 
Emirates, Azerbaijan, Kuwait, Saudi Arabia, and 
Qatar; while Germany, Saudi Arabia, U.S., 
Japan, and Liberia were identified as potential 
targets (15).
Shahiki Tash (2013) used indicators such as 
concentration ratio, Herfindahl-Hirschman, 
Tideman-Hall, comprehensive concentration, 
entropy concentration, and the Hannah-Kay 
indexes to determine Iran’s automotive market 
structure in 1996, 2001, 2006, and 2011. The 
results of this study revealed a high concentration 
in Iran’s automotive industry in spite of the 
emergence of new firms in that industry and the 
increasing production (16).
Macit (2012) used concentration ratio and 
Herfindahl-Hirschman index to investigate 
concentration and competition in the Turkish 
banking sector with empirical evidence over the 
period 2005-2010. He found no significant 
change in the degree of concentration from 
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2005. The results also showed that the Turkish 
banking sector is characterized by monopolistic 
competition and the degree of competition has 
decreased over the studied period (17).
Kramarić and Kitić (2012) analyzed the 
market structure and the degree of concentration 
of insurance markets in new EU member states 
with several indices such as concentration ratio, 
Herfindahl-Hirschman index, and entropy index. 
The results showed that the level of concentration 
decreased in all the observed countries, while in 
some countries it remained very high (18).
Experimental
Market Structure
Market structure lies somewhere between 
monopoly and perfect competition. These 
structures differ in various features such as the 
number of companies, degree of freedom of 
entry and exit, information, homogeneity of 
products, and economic benefits. Perfectly 
competitive or monopolistic markets are rare. 
Market structure represents organizational 
features of the market with which the relationship 
between market components can be determined. 
In fact, market structure is a set of variables that 
show the market’s pricing and competition (19).
The main organizational features of the 
market are concentration of sellers and buyers, 
entry conditions, and product differentiation. 
Seller concentration is determined by the number 
of sellers and their distribution. Buyer 
concentration refers to distribution of products 
among different buyers. Higher percentage of 
product purchased by a small number of buyers 
indicates that higher buyer concentration and 
producers will not be able to set and establish 
their own price. In an extreme situation called 
monopsony a large buyer controls a large 
proportion of the market (19).
Product differentiation (homogeneous and 
non-homogenous) is an important market 
structure variable. Buyers may prefer some 
products over others due to differences in quality, 
design and packaging, and/or reputation and 
validity. Entry condition indicates the difficulty 
or ease of entry into a market. If market entry is 
difficult, the firms may choose to cooperate 
and collude and adopt non-competitive 
behavior (20).
The number of firms and firm size (scale) are 
two very important market structure variables. A 
market with a small number of firms will most 
likely be monopolistic. Also a market with a 
large firm and a number of small firms is more 
likely to be monopolistic than a market with a 
few firms of more or less equal size (20).
There are various indices in applied 
economics for measuring market structure, but 
Concentration Ratio (CR) and Herfindahl-
Hirschman Index (HHI) are the most precise and 
well-known market structure indicators, so these 
were used in this study. Concentration ratio is 
the sum of the market shares of the i largest 
firms in a market, where i is a small number. The 
most common concentration ratios are CR4 and 
CR8, which indicate the market share of the four 
and the eight largest firms. The largest firm 
concentration ratio is CR1, which indicates 
monopoly, while in competitive markets CR1, 
CR4, CR8, and CR16 are common ratios. 
Concentration ratio can show the extent of 
market control of the largest firms in the industry 
and to illustrate the degree to which an industry 
is oligopolistic (21).
The Herfindahl index, proposed by Orris C. 
Herfindahl (1989), is a measure of the size of 
firms in relation to the industry and an indicator 
of the amount of competition among them. It is 
calculated from the following formula:
where si is the market share of firm i in the 
market, and N is the number of firms. In this 
paper the number of countries and their relative 
share from the market are placed in the formula. 
The Herfindahl index can range from 0 to 1.0, 
moving from a huge number of very small firms 
to a single monopolistic producer (22).
Target Markets
Target markets are a set of customers that a 
business aims its marketing efforts and its 
merchandise towards. A variety of marketing 
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where s� is the market share of firm i in the market, and N is the number of firms. In this paper 
the number of countries and their relative share from the market are placed in the formula. The 
Herfindahl index can range from 0 to 1.0, moving from a huge number of very small firms to a 
single monopolistic producer (22). 
 
Target Markets 
arget markets are a set of customers that a business aims its marketing efforts and its 
merchandise towards. A variety of marketing strategies can be used to penetrate target markets. 
An international market with stable and continuous growth in demand and proper economies of 
scale can be considered as a target market. Modern marketing requires an accurate definition of 
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continuous growth in demand and proper 
economies of scale can be considered as a target 
market. Modern marketing requires an accurate 
definition of target markets to be successful, as 
it will lead to better advertising and sales. 
Accurate identification of target markets is an 
important fact for the success of direct marketing 
(23).
In order to determine the target markets for 
Iran’s pharmaceutical exports, those countries 
that already had close economic ties with Iran 
and meanwhile were pharmaceutical importers 
from the world market were identified. Next, 
four following indicators of Iran’s pharmaceutical 
exports were evaluated and target markets for 
Iran’s pharmaceutical products were introduced 
based on the composite index of target market.
Import demand size: Taking into consideration 
only import demand rates, the number of 
countries that can be seen as potential target 
markets is determined by the percentage of 
world pharmaceutical import demand they 
make.
Import demand Index: Target markets for 
Iran’s pharmaceutical exports are those with an 
import demand index more than 100 in 2012 
(assuming that 2001 = 100).
Import for domestic consumption: This 
includes countries that import pharmaceutical 
products for domestic consumption.
Countries share of Iran’s exports: This 
includes countries with a small share of Iran’s 
pharmaceutical exports and a larger share of 
world pharmaceutical exports.
Composite index of target market: It implies 
countries that have the following three features: 
First, those countries encompass more than 0.1 
percent of world pharmaceutical imports; 
Secondly, pharmaceuticals has imported for the 
purpose of domestic consumption and the share 
of exports to imports for the given country is 
about zero; Thirdly, the given country does not 
account for a significant share of Iran›s 
pharmaceutical export and its share of the world 
imports is far more than Iran’s pharmaceutical 
export share to that country.
The related information and data were 
obtained from Iran’s pharmaceutical Statistics, 
World Bank, and International Trade Center (24-
26). 
Results
The structure of the world pharmaceutical 
market
In this section, we calculate concentration 
ratios to provide insights into the degree of 
competition and monopoly in the world 
pharmaceutical market.
Concentration in the world market was 
calculated based on the supply side (export) and 
the demand side (import) variables. More 
specifically, the Herfindahl index and 
concentration ratios of 1, 4, 8, and 16 firm were 
used to measure the market concentration in 
2001-2012. Accordingly, the structure of the 
world pharmaceutical market (monopoly, 
competitive, hard/soft oligopoly, or dominant 
firm) and its changes over the period 2001-2012 
were examined.
Germany, U.S., England, France, Switzerland, 
Belgium, Ireland, Netherlands, and Italy were 
the largest pharmaceutical exporters in the world 
in the years 2001-2012. In the export side of the 
world pharmaceutical market concentration 
ratios of 14.68%, 45.64%, 73.79%, and 90.37% 
were obtained for the 1, 4, 8, and 16 firm 
respectively for 2001-2012. The Herfindahl 
index in the export side of the world 
pharmaceutical market was 0.079 during this 
period. The inverse Herfindahl index (IHI) was 
12.61 as were shown in Table 1.
The 1, 4, 8, and 16 firm (country) 
concentration ratios in the export side of the 
world pharmaceutical market changed from 
14.26%, 45.81%, 74.34%, and 91.24% in 2001 
to 14.79%, 45.16%, 70.71%, and 87.88% in 
2012. In addition, the Herfindahl index in the 
export side of the world market changed from 
0.0793 in 2001 to 0.0747 in 2012. IHI increased 
from12.62 in 2001 to 13.39 in 2012.
In the years 2001-2012, U.S., Germany, 
England, Belgium, France, Switzerland, Italy, 
Japan, Spain, and the Netherlands were the 
largest importers from the world pharmaceutical 
market. In the period 2001-2012, the 1, 4, 8, and 
16 firm (countries) concentration ratios in the 
import side of the world pharmaceutical were 
13.75%, 40.29%, 58.97%, and 75.82% 
respectively. The Herfindahl index was 0.0576, 
and IHI was 17.50 in this period (Table 2).































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Concentration ratios in the import side of the 
world pharmaceutical market changed from 
13.73%, 35.14%, 55.10% and 73.24% in 2001 to 
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but these changes were not significant. 
Additionally, the Herfindahl index in the import 
side changed from 0.0499 in 2001 to 0.0497 in 
2012, while IHI changed from 20.06 in 2001 to 
20.11 in 2012.
The structure of Iran›s pharmaceutical 
exports to its business partners
Table 3 shows the structure of Iran’s 
pharmaceutical exports to its business partners 
in 2012. In this year, Afghanistan, Russia, Iraq, 
Pakistan, Ukraine, Syria, Yemen, and Tajikistan 
were the major pharmaceutical importers from 
Iran. 1, 4, 8 and 16 country concentration ratios 
were 42.03%, 68.05%, 82.32%, and 92.57% 
respectively, indicating that while Iran’s 
pharmaceutical products were exported to 70 
countries, the top eight countries imported about 
70% of these products. The Herfindahl index 
was 21.1% for 2012, indicating the monopoly of 
a few countries over Iran’s pharmaceutical 
market. These eight countries had an even share 
of Iran’s total pharmaceutical exports and thus 
the exports structure of Iran is a form of closed 
oligopoly.
Although a few countries have a monopoly 
over Iran’s pharmaceutical market, they are not 
stable clients. However, the number of countries 
that import pharmaceutical products from Iran is 
increasing and Iran’s pharmaceutical exports 
structure is shifting to open oligopoly. 
Target markets for Iran pharmaceutical 
exports
To identify and prioritize the target markets 
for Iran’s pharmaceutical exports, target market 
composite index was used. This index expresses 
the size of imported demand, imports for 
domestic consumption and the share of countries` 
exports from Iran. These indicators were 
evaluated annual trade statistics from UN 
Comtrade (27) and International Trade Centre 
(ITC) databases for the period 2001-2012. 
Potential target markets for Iran’s pharmaceutical 
exports are listed in Table 4.
According to target market composite Index, 
27 countries from 225 countries that have been 
imported pharmaceutical products from the 
world market (represented in the Table 4) are the 
most appropriate countries with the highest 
priorities for developing export market and 
should be considered carefully as a 
pharmaceutical target markets of Iran.
Discussion
The Herfindahl index and concentration 
ratios showed that the export side of the world 
pharmaceutical market is evenly distributed 
among 15-20 countries. In other words, the 
structure of the export side is open oligopoly, 
with 4 countries having a monopoly over 45% of 
the market. The increase in concentration ratios 
over the studied period indicate that the 
monopolistic control of exporters over the world 
pharmaceutical market has decreased and the 
structure of the world market export is shifting 
to open oligopoly.
The results also showed that the import side 
of the world pharmaceutical market is evenly 
distributed among 15-20 countries. In other 
words, the structure of the import side of the 
world pharmaceutical market is monopolistic 
competition; that is, the number of competing 
Table 3. The structure of Iran’s pharmaceutical exports to its business partners in 2012.
Concentration ratios Herfindahl index
StructureCR1 CR4 CR8 CR16
Largest importers
HI IHI
(%) (%) (%) (%) (0-1) (Number)
42.03 68.05 82.32 92.57 Afghanistan, Russia, Iraq, Pakistan, Ukraine, Syria, Yemen, Tajikistan 0.211 4.72 Closed oligopoly 
Although a few countries have a monopoly over Iran’s pharmaceutical market, they are not stable clients. However, the number of 




countries are high and they do not have 
monopolistic control over more than 15% of the 
market. Concentration ratios did not change 
significantly over the studied period, indicating 
that importers have maintained their monopolistic 
control and the structure is still monopolistic 
competition. 
A comparison of the export and import side 
of the world pharmaceutical market suggests 
that the import side is more competitive than the 
export side. Thus, it is the importers and not the 
exporters that dominate the world pharmaceutical 
market.
Examining the structure of Iran’s 
pharmaceutical exports revealed that Iran’s 
major business partners changed over the studied 
period due to lack of stability in the market. 
However, recent increase in the number of 
importers from Iran’s pharmaceutical market 
has reduced the monopolistic power of Iran’s 
business partners.
Among the 225 countries that import from 
the world pharmaceutical market, there are at 
least 27 countries with appropriate distance and 
consumption pattern (Low-income developing 
countries) which are the best candidates to be 
considered as target markets for Iran’s 
pharmaceutical exports.
The major importers from Iran’s 
pharmaceutical market during the study period 
were Iraq, Afghanistan, and some member 
countries from the Common wealth of 
Independent States (CIS). However, this study 
identified Pakistan, Syria, Armenia, UAE, 
Tajikistan, Uzbekistan, Azerbaijan, and some 
other countries as potential target markets for 
Iran’s pharmaceutical exports. 
Pharmaceutical firms can choose a number 
of high-priority markets with respect to their 
capabilities and potentials, and penetrate those 
markets using an integrated marketing plan that 
focuses on information about competitors, the 
marketing mix, and relevant rules and 
regulations.
The results suggested that the potential 
markets for Iran’s pharmaceutical exports are 
mainly regional markets. In addition, some of 
these countries have low rankings on the list of 
priority markets. This does not mean that export 
to these markets should be limited; rather 
penetration into these markets should be 
accelerated with an accurate marketing plan 
given the growth in demand as well as the 
increasing potential for competition.
To achieve a proper place in the international 
pharmaceutical trade, the following strategies 
are recommended:
Diversifying target markets for exports;
Table 4. Target markets for Iran’s pharmaceutical exports.























23 Saudi Arabia 32.56
24 Uganda 30.69
25 Lebanon 29.86
26 Czech Republic 27.12
27 Italy 25.66
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Strengthening marketing and packaging 
infrastructure based on standards and consumer 
needs;
Facilitating export laws and eliminating 
shortcomings in product transportation;
Developing production and export 
organizations by emphasizing on production for 
export purposes;
Reinforcing trade associations (government 
support for facilitating export by creating 
integrated marketing associations, establishing 
sales offices in target countries, and holding 
pharmaceutical exhibitions in target countries);
Prioritizing target markets based on import 
demand size, import demand index, import for 
domestic consumption, and countries’ share of 
exports;
Developing exports to target countries 
through mechanisms such as preferential tariffs 
trade agreements, effective promotion, 
exhibitions, quality assurance, and attention to 
standard as well as consumer tastes and 
preferences (28);
Participation of pharmaceutical companies in 
exhibitions with financial support by the 
government;
Formation of holding companies in which 
case the composition and structure of 
pharmaceutical companies change and the 
companies will cooperate and not compete;
Solving the marketing and financing 
problems of small pharmaceutical companies 
through brand licensing;
Creating pharmaceutical export associations 
and unions.
Conclusion
Prioritizing target markets of pharmaceutical 
export, based on the target market composite 
index, indicates Iraq and Afghanistan as the first 
priority to be considered as target countries for 
Iran pharmaceutical export. Pakistan, Syria, and 
other countries of target markets for Iran’s 
pharmaceutical exports take the next order in 
this list. Given the current position of Iran’s 
pharmaceutical export to different countries, 
there is a significant difference between actual 
and potential markets; this means that the 
potential target markets aren’t mainly the same 
as the current markets. Meanwhile, considering 
the lack of a classified and comprehensive 
marketing strategy framework for pharmaceutical 
export, it is necessary to develop a pharmaceutical 
export strategy based on prioritized target 
markets to develop practical strategies for 
exporters and the country`s business planning 
authorities.
Proper management of the pharmaceutical 
industry can earn huge revenue through 
pharmaceutical export. The present findings 
provide useful information that can be crucial 
for pharmaceutical companies and policymakers 
who are involving in promoting pharmaceutical 
export in Iran.
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